Compare AUUD & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUUD | ONCO |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.3M |
| IPO Year | N/A | 2021 |
| Metric | AUUD | ONCO |
|---|---|---|
| Price | $0.80 | $0.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 539.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,524,116.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4217.31 |
| 52 Week Low | $0.21 | $0.05 |
| 52 Week High | $7.29 | $7.65 |
| Indicator | AUUD | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 33.90 |
| Support Level | $0.66 | $0.07 |
| Resistance Level | $1.20 | $0.95 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 24.26 | 19.66 |
Auddia Inc is a United States-based company. It operates through its proprietary AI platform for audio and is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. The group Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Its flagship audio superapp, called faidr, delivers multiple industry firsts, including: Ad-free listening on any AM/FM radio station, Content skipping across any AM/FM station, One-touch skipping of entire podcast ad breaks, and Integrated artist discovery experiences.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.